Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$72.66 USD

72.66
1,655,312

-1.01 (-1.37%)

Updated Aug 27, 2024 02:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Will Admissions Drive Universal Health's (UHS) Q4 Earnings?

Solid performances at Acute Care and Behavioral Health segments are likely to boost Universal Health's (UHS) Q4 results.

    Why DexCom (DXCM) Might Surprise This Earnings Season

    DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      DexCom Estimates Strong Revenue Figures for Q4 and 2017

      Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.

        The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom

        The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom

          4 MedTech Stocks to Explode in 2018

          Standing at the threshold of 2018 it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more.

            DexCom (DXCM) Banks on Collaborations, Competition Rife

            DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.

              Lilly Inks Deal to Include Dexcom Products in Diabetes System

              Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.

                DexCom-Lily Partnership to Boost CGM Platform, Customer Base

                DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

                  DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet

                  DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.

                    Why Is DexCom (DXCM) Up 11.6% Since the Last Earnings Report?

                    DXCM reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      DexCom (DXCM) in Focus: Stock Moves 6.7% Higher

                      DexCom, Inc. (DXCM) was a big mover last session, as the company saw its shares rise nearly 7% on the day after the company reported better-than-expected third quarter, 2017 results.

                        DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat

                        DexCom (DXCM) recorded narrower-than-expected loss in the second quarter owing to robust growth in international space, particularly Germany.

                          Company News for June 06, 2017

                          Companies in the News are: HLF,P,VZ,PBYI,DXCM,AAPL

                            Strength Seen in DexCom (DXCM): Stock Adds 5% in Session

                            DexCom, Inc. (DXCM) shares rose over 5% in the last trading session.

                              Ryan McQueeney headshot

                              DexCom (DXCM) Stock Rallies on Apple Watch Partnership

                              Shares of DexCom (DXCM) popped nearly 5% in afternoon trading Monday after Apple (AAPL) announced that it has partnered with the company to deliver glucose monitoring on its latest Apple Watch operating system.

                                DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound?

                                DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss

                                  DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.

                                    Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More

                                    The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.

                                      DexCom (DXCM) Up 4.6% Since Earnings Report: Can It Continue?

                                      DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        DexCom Gains as CMS Announces Criteria for G5 Mobile CGM

                                        The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.

                                          DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues

                                          DexCom Inc. (DXCM) reported loss of nine cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents.

                                            Should You Buy DexCom (DXCM) Ahead of Earnings?

                                            DexCom (DXCM) looks like an exciting pick for investors as it is poised to beat at earnings season.

                                              DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?

                                              DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.

                                                DexCom Looking Forward to Strong Revenues in Q4 and 2016

                                                DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.

                                                  DexCom (DXCM) Gains FDA Approval for G5 Mobile CGM System

                                                  San Diego, CA-based DexCom, Inc. (DXCM), a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system.